ANGPT2 and glioblastoma: In conclusion, our data indicate that an MMS consisting of four antagonistic angiogenesis ligand pairs (VEGF-A, VEGF-B and ANG1, ANG2) can successfully demarcate proneural and mesenchymal subtype cells in glioblastoma.